TrialLancet (London, England)2021

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.

Sumanta K Pal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.